MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator’s Global Assessment
NEW YORK and LONDON, February 17, 2015 (GLOBE NEWSWIRE) — Celsus Therapeutics (NASDAQ: CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. MRX-6 cream did not demonstrate a difference in mean change from baseline to Day 28 in the Investigator’s Global Assessment (IGA):
